Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma

Cancer

Volumn 119, Issue 1, 2013, Pages 136-142

  Lee, Joo Ho ^a   Chung, Young Hwa ^a   Kim, Jeong A ^a   Shim, Ju Hyun ^a   Lee, Danbi ^a   Lee, Han Chu ^a   Shin, Eun Soon ^b   Yoon, Jung Hwan ^c   Kim, Byung Ik ^d   Bae, Si Hyun ^e   Koh, Kwang Cheol ^f   Park, Neung Hwa ^g  

^a University of Ulsan College of Medicine   (South Korea)

^b DNA Link Inc   (South Korea)

^c Seoul National University Hospital   (South Korea)

^d School of Medicine   (South Korea)

^e The Catholic University of Korea   (South Korea)

^f Samsung Medical Center   (South Korea)

^g University of Ulsan   (South Korea)

Author keywords

hand foot skin reaction; hepatocellular carcinoma; sorafenib; tumor necrosis factor alpha; vascular endothelial growth factor

Indexed keywords

GLUCURONOSYLTRANSFERASE 1A9; SORAFENIB; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; CANCER PATIENT; CANCER STAGING; CHEMOEMBOLIZATION; COHORT ANALYSIS; DIARRHEA; DRUG INDUCED DISEASE; ETHNIC DIFFERENCE; FATIGUE; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENOTYPE; HAND FOOT SKIN REACTION; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INCIDENCE; KOREA; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; ONCOGENE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PRURITUS; RASH; RISK FACTOR; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE COUNT; TNF A GENE; TREATMENT DURATION; UGT1A9 GENE; UNIVARIATE ANALYSIS; VEGF GENE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAND-FOOT SYNDROME; HUMANS; KOREA; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRIDINES; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84872771082     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27705     Document Type: Article

References (30)

1. Shim JH, Park JW, Choi JI, et al. Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a hepatitis B virus-endemic area. J Cancer Res Clin Oncol. 2009; 135: 617-625.
2. Llovet JM, Fuster J, Bruix J,. Prognosis of hepatocellular carcinoma. Hepatogastroenterology. 2002; 49: 7-11.
3. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002; 359: 1734-1739.
4. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 378-390.
5. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 25-34.
6. Newell P, Villanueva A, Llovet JM,. Molecular targeted therapies in hepatocellular carcinoma: from pre-clinical models to clinical trials. J Hepatol. 2008; 49: 1-5.
7. Chu D, Lacouture ME, Fillos T, et al. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol. 2008; 47: 176-186.
8. Azad NS, Aragon-Ching JB, Dahut WL, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res. 2009; 15: 1411-1416.
9. Candelaria M, Taja-Chayeb L, Arce-Salinas C, et al. Genetic determinants of cancer drug efficacy and toxicity: practical considerations and perspectives. Anticancer Drugs. 2005; 16: 923-933.
10. Giacalone A, Montalto G, Giannitrapani L, et al. Association between single nucleotide polymorphisms in the cyclooxygenase-2, tumor necrosis factor-alpha, and vascular endothelial growth factor-A genes, and susceptibility to hepatocellular carcinoma. OMICS. 2011; 15: 193-196.
11. Liu JG, Zhao HJ, Liu YJ, et al. Effect of selenium-enriched malt on VEGF and several relevant angiogenic cytokines in diethylnitrosamine-induced hepatocarcinoma rats. J Trace Elem Med Biol. 2010; 24: 52-57.
12. Jung KW, Ha E, Yu GI, et al. TNFalpha promoter polymorphism is a risk factor for susceptibility in hepatocellular carcinoma in Korean population. Clin Chim Acta. 2009; 407: 16-19.
13. Dikov MM, Ohm JE, Ray N, et al. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol. 2005; 174: 215-222.
14. Ueno S, Tanabe G, Nuruki K, et al. Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis. Hepatol Res. 2002; 24: 395-403.
15. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006; 24: 2505-2512.
16. Dahut WL, Scripture C, Posadas E, et al. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res. 2008; 14: 209-214.
17. Lai SE, Kuzel T, Lacouture ME,. Hand-foot and stump syndrome to sorafenib. J Clin Oncol. 2007; 25: 341-343.
18. Kane RC, Farrell AT, Saber H, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res. 2006; 12: 7271-7278.
19. Schneider BP, Wang M, Radovich M, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 200; 26: 4672-4678.
20. Tsai KY, Yang CH, Kuo TT, et al. Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma. J Clin Oncol. 2006; 24: 5786-5788.
21. Carmeliet P, Jain RK,. Angiogenesis in cancer and other diseases. Nature. 2000; 407: 249-257.
22. van Horssen R, Ten Hagen TL, Eggermont AM,. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist. 2006; 11: 397-408.
23. Ryu SH, Chung YH,. How to overcome multidrug resistance in chemotherapy for advanced hepatocellular carcinoma. Liver Int. 2010; 30: 496-498.
24. Ho SY, Wang YJ, Chen HL, et al. Increased risk of developing hepatocellular carcinoma associated with carriage of the TNF2 allele of the -308 tumor necrosis factor-alpha promoter gene. Cancer Causes Control. 2004; 15: 657-663.
25. Panguluri RC, Long LO, Chen W, et al. COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis. 2004; 25: 961-966.
26. Kroeger KM, Steer JH, Joyce DA, et al. Effects of stimulus and cell type on the expression of the -308 tumour necrosis factor promoter polymorphism. Cytokine. 2000; 12: 110-119.
27. Fajardo LF, Kwan HH, Kowalski J, et al. Dual role of tumor necrosis factor-alpha in angiogenesis. Am J Pathol. 1992; 140: 539-544.
28. Naredi PL, Lindner PG, Holmberg SB, et al. The effects of tumour necrosis factor alpha on the vascular bed and blood flow in an experimental rat hepatoma. Int J Cancer. 1993; 54: 645-649.
29. Lejeune FJ, Lienard D, Matter M, et al. Efficiency of recombinant human TNF in human cancer therapy [serial online]. Cancer Immun. 2006; 6: 6.
30. International HapMap Consortium. A haplotype map of the human genome. Nature. 2005; 437: 1299-1320.